Ironwood Pharma (I76) AI Stock Analysis

Ironwood Pharma

(Frankfurt:I76)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

LINZESS growth and raised guidanceStrong LINZESS demand is translating into materially higher sales expectations, with management raising both product and company guidance. Continued prescription growth and improved net price can support recurring collaboration profits, strengthen operating leverage, and provide funding for debt reduction and pipeline investment.

Negative Factors

Dependence on a single core productRevenue concentration in LINZESS makes overall performance highly sensitive to demand, pricing, and collaboration economics for one product. Even with current growth, a setback in the franchise would have an outsized effect on cash generation, development funding, and the company’s ability to sustain its recovery.

Ironwood Pharma (I76) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 571.73M
Dividend Yield: ―
Average Volume (3M): 3,048
Price to Earnings (P/E): 4.3
Beta (1Y): 0.95
Revenue Growth: 18.10%
EPS Growth: ―
Country: Germany
Employees: 100
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Ironwood Pharma Business Overview & Revenue Model

Company Description

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guany...

Ironwood Pharma Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:-16.57%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentPositive

The call conveyed a predominantly positive commercial and financial story driven by LINZESS: strong Q2 sales, significant YTD growth, an upward revision to full-year guidance, a pediatric label expansion, and robust quarterly profitability. Clinical progress on apraglutide (initiation of STARS-2 and supportive STARS/STARS-Extend data) and actions to strengthen the balance sheet (repayment of convertible notes and target to reduce gross leverage) are additional positives. Offsetting risks include dependence on LINZESS for revenue, early-stage enrollment uncertainty for STARS-2, remediation required after a prior dosing kit error, anticipated higher R&D/SG&A spend in H2, and a modest cash balance that increases reliance on operating cash flow and receivables.

Positive Updates

Strong LINZESS Commercial Performance

Q2 U.S. net sales for LINZESS were $282.3M (14% year-over-year). Year-to-date (first half) LINZESS U.S. net sales reached $555M, up 44% YoY. Q2 EUTRx volume growth was +4% YoY and +5% year-to-date, with management expecting mid-single-digit demand growth for the full year.

Negative Updates

Concentration Risk on LINZESS

Company remains heavily dependent on LINZESS as the primary revenue driver (relying on continued price and demand improvements) which concentrates commercial risk in a single product despite strong current performance.

Company Guidance

Ironwood raised full‑year 2026 guidance driven by LINZESS strength, now expecting LINZESS U.S. net sales of $1.15–$1.20 billion (greater than 30% year‑over‑year growth) supported by mid‑single‑digit prescription demand growth and improved net price; company revenue guidance is $460–$485 million and adjusted EBITDA is expected to be greater than $310 million. In Q2 LINZESS U.S. net sales were $282.3 million (H1 net sales $555 million, +44% YTD), EUTRx volume growth was +4% in Q2 and +5% YTD, and management expects sequential quarterly net sales to build with Q4 as the strongest quarter. Q2 company results included total revenue of $113 million, GAAP net income of $51.3 million and adjusted EBITDA of $83 million; the company ended the quarter with $79 million cash, $113 million collaboration receivables, repaid $200 million of convertible notes, and expects to finish 2026 with gross debt under $300 million and gross leverage below 1x while using LINZESS cash flow to further reduce debt.

Ironwood Pharma Risk Analysis

Ironwood Pharma disclosed 46 risk factors in its most recent earnings report. Ironwood Pharma reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.Item 1A. Risk FactorsQ1, 2026

Ironwood Pharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:I76 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RDY	67Neutral	$11.89B	39.94	7.37%	0.79%	-10.52%	-55.45%
COLL	64Neutral	$774.82M	15.48	15.96%	―	14.31%	34.35%
HLN	62Neutral	$37.65B	17.82	9.89%	2.26%	4.99%	12.37%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRGO	43Neutral	$2.19B	-1.26	-55.97%	7.37%	-4.18%	-2138.82%
CPIX	35Underperform	$70.27M	-5.91	-47.10%	32.85%	-25.68%	-244.92%

* Healthcare Sector Average

Performance Comparison

DE:I76 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:I76	Ironwood Pharmaceuticals	3.02	1.33	78.70%
RDY	Dr. Reddy's Laboratories Ltd	14.13	0.80	6.03%
PRGO	Perrigo Company	15.75	1.95	14.14%
COLL	Collegium Pharmaceutical Inc.	23.68	-12.17	-33.95%
CPIX	Cumberland Pharmaceuticals Inc.	4.22	2.41	133.67%
HLN	Haleon PLC Sponsored ADR	8.76	-0.38	-4.11%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Ironwood Pharma AI Stock Analysis